Pyxis Oncology rises on FDA fast track tag for lead asset
Source: SeekingAlpha
2025-02-26 07:55:47 ET
Shares of Pyxis Oncology ( NASDAQ: PYXS ) traded higher in the premarket on Wednesday after the U.S. FDA issued its Fast Track Designation for the company’s lead candidate, PYX-201, targeted at head and neck cancer....
Read the full article on Seeking Alpha
For further details see:
Pyxis Oncology rises on FDA fast track tag for lead asset
Merck & Company Inc.
NASDAQ: MRK
MRK Trading
1.11% G/L:
$116.48 Last:
2,106,719 Volume:
$116.92 Open:
MRK Latest News
March 05, 2026 10:20:00 am
Forget ImmunityBio: This Big?Cap Pharma Is the Safer Play on Next?Gen Cancer Therapies
March 03, 2026 09:00:00 am
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
MRK Stock Data
$291,612,827,755
2,457,202,311
0.02%
2165
N/A
Pharmaceuticals
Healthcare
US
Rahway
